An interventional study of Reusable Underwear and Disposable urethral support in Urinary Incontinence and Cystic Fibrosis, sponsored by Megan Bradley. Terminated at 1 site in United States. Open to female participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-10-01.
Sponsored by Megan Bradley · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 293 studies in Urinary Incontinence with a site in United States — 33 open to participants now, 47 under way, 3 of them phase 3. Urinary Incontinence · United States.
Among the 293 studies in Urinary Incontinence with a site in United States, this one is the 215th largest by enrollment of the 249 interventional ones that give a count, is one of 14 that started in 2021, is one of 144 with no phase, and was the 222nd registered.
988 studies on the registry are indexed under Urinary Incontinence; 184 are open to participants now.
Browse Urinary Incontinence studies →33 of the 293 studies in Urinary Incontinence with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States, Canada
Ages 18+ · Women only
Duke University · Sites in United States
Ages 18+ · Men only
Ohio State University · Sites in United States
Ages 18+ · Women only
The Methodist Hospital Research Institute · Sites in United States
Ages 22–80 · Men only · Healthy volunteers
University of Miami · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 113 Urinary Incontinence studies recruiting now, 63 (56%) set no upper age limit and 35 (31%) stop at 75 or younger; 15 take children under 18; 28 take healthy volunteers.
This study: 18 Years to 99 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
293 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 23 · Phase 3 38 · Phase 4 35
First in 1993; this study’s year is marked. 14 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 66 across 743 interventional studies indexed under Urinary Incontinence.
Median enrollment 75 across the 249 interventional studies, 100 across the 43 observational. Of the 219 that completed or were terminated, 105 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
87 of 293 have an industry lead sponsor. The 10 most frequent:
Megan Bradley is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Megan Bradley has 1 study filed under Urinary Incontinence — fewer than ten, so there is no comparison to draw.
16 of the studies in Urinary Incontinence with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07387315TriHealth Inc.A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections | 2026-11 |
| NCT04565925The University of Texas Medical Branch, GalvestonSildenafil for Treatment of Urinary Incontinence in Patients With Spinal Cord Injuries | 2026-12-01 |
| NCT07534696University of California, Los AngelesEvaluation of Non-Invasive Pelvic Floor Neuromuscular Stimulation for Urinary Incontinence After Prostatectomy | 2026-12-31 |
| NCT06226220University of ChicagoPercutaneous Nerve Evaluation Trial Time | 2026-12-31 |
| NCT06369922University of RochesterTENS Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence. | 2027-01-31 |
Add all 16 to your calendar (.ics) → With an account.
Among the 293 studies in Urinary Incontinence with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Evaluate the feasibility of a randomized controlled trial of non-surgical urinary incontinence (UI) management options for women with CF. The investigators will complete a pilot, feasibility study (n=30) to compare tolerability and symptom relief in women with CF and UI. Subjects will be recruited from the University of Pittsburgh Cystic Fibrosis Center after demonstrating bother from UI on initial phone script. Participants will undergo UI questionnaires and undergo a pelvic examination, non-invasive bladder scan ultrasound and a provocative stress test and then be randomized to either a disposable urethral support device (Impressa®), an absorbent product (Speax Reusable Underwear), or Pelvic floor muscle therapy. The primary outcome will be to determine the feasibility and tolerability of these options.
Hypothesis: All three non-surgical UI management options for women are feasible (as measured by 80% adherence to treatment assignment over 7 days) and tolerable (as measured by patient report via questionnaire).
The results from the proposed aims will provide important information about the experiences and symptom burden of women with CF and UI. Importantly, the investigators will also be able to answer the important questions of "Can it work?" and "Does it work?" as the investigators seek to construct the definitive, adequately powered trial of these therapies in women with CF and UI.
Study Procedures: Participants will be recruited at routine cystic fibrosis (CF) clinic visits and via telephone screening. The investigators will again utilize the ISI for screening procedures with subjects required to have at incontinence at least as frequent as 'less than once a month' and at least as 'drops' to be eligible for enrollment. Informed consent will be obtained before any study procedures are initiated. Initial demographic questions and the King's Health Questionnaire (KHQ) will be completed at the baseline visit. Subjects will be given materials to complete a 2-day bladder diary. The bladder diary has participants track what they take in (fluids) and also their voided volumes throughout the day and night. Subjects will be given a hat to void in a collect the numbers/volume of voids and also leakage episodes. Pregnancy will be excluded by self-report. Participants will then have a pelvic exam for a visual urethral mobility examination and assessment of pelvic floor muscle strength to be completed by the principal investigator. The principal investigator will additionally first perform a bladder scan ultrasound to assess current bladder volume and then a cough stress test (CST). The exam will be performed in the supine/lithotomy position with ≥300 mL of fluid in the bladder. The investigators will have the subject cough forcefully 1-4 times and the examiner will directly visualize the urethral meatus for the presence of leakage. Leakage of fluid from the urethral meatus coincident with/simultaneous to the cough(s) is considered a positive test consistent with stress urinary incontinence (SUI).
Randomized feasibility trial (Table 2). At the baseline visit, women will be given a brief description of the three different treatment options and be initially asked to rank initial choice for treatment. Participants will then be randomized to either a disposable urethral support device (Impressa®), Speax™ Reusable Underwear, or pelvic floor muscle therapy (PFMT). Randomization will be in a 1:1:1 allocation without stratification by incontinence severity. The disposable Impressa® urethral support is a tampon-like device that is available over the counter to help women with urinary incontinence (UI). Speax Reusable Underwear are similarly available for purchase online and are absorbent underwear for bladder leak protection. Both the Impressa and Speax are commercially available and the Impressa is FDA approved. The Speax underwear are not a FDA regulated product. Urethral support device cohort - A week supply of the Impressa device will be provided and participants will be asked to complete a daily bladder diary for a total of 7 days. The instructions for use booklet will be provided. Subjects will be told that they can continuously utilize one Impressa for up to 12 hours. The investigators will ask subjects to wear for at least 12 hours a day but up to 24 if they desire. Reusable absorbent pad cohort - Three pairs of Speax underwear will be provided and subjects will complete a similar daily UI diary for 7 days. Subjects will be instructed to wear one pair of speax daily and may wash as they desire. Subjects will be provided the website for the product and The investigators will allow them to order whatever pair/size the subject desires. https://www.shethinx.com/pages/speax. PFMT cohort - Experienced pelvic health physical therapists (at both University of Pittsburgh) will complete two visits one week apart. Each PFMT visit will take \~60 minutes. The investigators will develop a standardized pelvic floor exercise intervention based on previous RCT for PFMT in women with MUI. The intervention will comprise: 1) Bladder training and delayed voiding techniques 2) Urgency suppression 3) SUI strategies (e.g., 'knack') and 4) Pelvic floor muscle (PFM) training for those agreeable to internal exams. The investigators will utilize Diaphragmatic breathing, Happy Baby Stretch with pelvic floor muscle (PFM) relaxation and lower abdominal myofascial release (MFR) to start. These are all non-internal stretching type exercises similar to yoga and will be performed for \~20-30 minutes. If the subject is willing the investigators will consider internal pelvic floor muscle training which will involve the physical therapist inserting one digit into the vagina in order to aid in muscle coordination. This will also be done for 20-30 minutes.
Subjects will not be blinded to their group assignment given the nature of the differences in management options. At the end of the treatment assignment all subjects will repeat the KHQ and a patient global impression of improvement (PGI-I). The PGI-I is a validated one question measure rating their urinary tract condition now, as compared with how it was prior to before beginning treatment on a scale from 1 (Very much better) to 7 (Very much worse). All subjects will complete the follow-up questionnaires 7-days after the beginning of their assigned therapy.
Given the opportunity to gather acceptability on these options for a sensitive issue, subjects will be offered an option to further participate in one alternate therapy of their choosing. If subjects select this option, investigators will organize an additional week of therapy. Participants will only have to complete a BSW questionnaire and another PGI-I at the end of therapy. This is an option for all women in the study even if they initially had been randomized to their preferred option as participants may ultimately have not really liked that choice.
Acceptability and Feasibility assessment: Urethral support device cohort and Reusable absorbent pad cohort: Feasibility will be evaluated through assessment of use and product performance. Logs regarding utilization of assigned product will be completed daily. Patient treatment preference will be assessed after completion of both therapies utilizing the product performance questionnaire (PPQ). The PPQ is a 13-item product questionnaire that consists of product questions that are specific to incontinence products and includes questions about overall impression of product, ability to hold urine, ability to prevent odor, fit, discreteness, comfort when wet and dry, and ability to keep skin dry. PFMT cohort: Feasibility will be evaluated through assessment of adherence and self-reported success with ability to perform exercises. Adherence to intervention sessions will be documented by physical therapist using attendance logs. Adherence to home practice will be documented by participants in home logs that included the dates and times of practice. At the end of each physical therapy visit, participants will be asked to rate their confidence in performing the PFMT exercises featured in their program (extremely, very, moderately, somewhat, and not at all confident).
At the end of the study, all participants will be asked to indicate how easy it would be to continue practicing their assignment intervention (extremely, very, moderately, somewhat, and not at all easy). All subjects will complete a Benefit, Satisfaction, and Willingness to Continue (BSW) questionnaire. The investigators will consider therapy feasible (as measured by 80% adherence to treatment assignment over 7 days) and tolerable (as measured by patient report via questionnaire). By allowing subjects to choose another one of the arms after their randomization this will give us further, important information about feasibility and patient preference for a larger trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
disposable urethral support device
Device: Disposable urethral support
Reusable Underwear
Device: Reusable Underwear
Pelvic floor muscle therapy
Behavioral: Pelvic floor physical therapy
Reusable Underwear are similarly available for purchase online and are absorbent underwear for bladder leak protection
The disposable urethral support is a tampon-like device that is available over the counter to help women with urinary incontinence (UI)
Experienced pelvic health physical therapists (at University of Pittsburgh) will complete two visits one week apart.
Patient Global Impression of Improvement-Incontinence
The Patient Global Impression of Improvement-Incontinence (PGI-I) is a validated one question measure rating their urinary tract condition now, as compared with how it was prior to before beginning treatment on a scale from 1 (Very much better) to 7 (Very much worse). It is a score calculated at Day 7.
Time frame: 7 days
Patient Treatment Preference
Patient treatment preference will be assessed after completion of initial assigned therapy utilizing the product performance questionnaire (PPQ). The PPQ is a 13-item product questionnaire that consists of product questions that are specific to incontinence products and includes questions about overall impression of product, ability to hold urine, ability to prevent odor, fit, discreteness, comfort when wet and dry, and ability to keep skin dry. Patients are allowed to answer each question with either "unacceptable (1)," "acceptable (2) ," or "good (3) " to each question. Therefor minimum on questionnaire is a 0 and maximum is 39 with higher score showing improved patient treatment preference/performance of product.
Time frame: 7 days
King's Health Questionnaire
The KHQ is a 21-item scale with 9 domains: general health perceptions, incontinence impact, role limitations, physical limitations, social limitations, personal relationships, emotions, Sleep/Energy, and severity measures and an 11-item symptom severity score. (Hebbar et al., 2015) Each question has four options "not at all", "a little", "moderately" and "a lot". (numerically 1-4) The general health perception domain has five choices ("very good", "good", "fair", "bad" and "very bad") (numerically 1-5). The scores are then converted to "out of 100" with accepted formulas. For example for Q1 the overall score = ((actual score-1)/4)\*100 In the KHQ, a minimum possible score of zero is assigned to the best health and a maximum possible score of 100 is assigned to the worst health. The 0-100 scale is used for each item and each subscale separately. You can then report a total average score across all domains which is reported here
Time frame: 7 days
Adherence Logs
Subjects will be asked to document their adherence to therapy on a daily basis and outcome will be reported as the percentage of participants with 100% adherence (responded yes to adherence to therapy all 7 days of therapy on their daily log)
Time frame: 7 days
Benefits, Satisfaction, and Willingness to Continue
At the end of the study, all participants will be asked to indicate how easy it would be to continue practicing their assignment intervention (extremely, very, moderately, somewhat, and not at all easy) and complete the Benefit, Satisfaction, and Willingness to Continue (BSW) questionnaire which asks "would you be willing to continue treatment with this product or therapy?" The reported outcome is the number of participants per group that answered "Yes" to this question.
Time frame: 7 days
| Milestone | Disposable Urethral Support Device | Reusable Underwear | Pelvic Floor Muscle Therapy (PFMT) |
|---|---|---|---|
| Started | 4 | 6 | 5 |
| Completed | 4 | 4 | 4 |
| Not completed | 0 | 2 | 1 |
The Patient Global Impression of Improvement-Incontinence (PGI-I) is a validated one question measure rating their urinary tract condition now, as compared with how it was prior to before beginning treatment on a scale from 1 (Very much better) to 7 (Very much worse). It is a score calculated at Day 7.
| score on a scale | Disposable Urethral Support Device | Reusable Underwear | Pelvic Floor Muscle Therapy (PFMT) |
|---|---|---|---|
| Patient Global Impression of Improvement-Incontinence | 2.25 ± 0.05 | 3.00 ± 0.05 | 3.75 ± 0.05 |
Patient treatment preference will be assessed after completion of initial assigned therapy utilizing the product performance questionnaire (PPQ). The PPQ is a 13-item product questionnaire that consists of product questions that are specific to incontinence products and includes questions about overall impression of product, ability to hold urine, ability to prevent odor, fit, discreteness, comfort when wet and dry, and ability to keep skin dry. Patients are allowed to answer each question with either "unacceptable (1)," "acceptable (2) ," or "good (3) " to each question. Therefor minimum on questionnaire is a 0 and maximum is 39 with higher score showing improved patient treatment preference/performance of product.
| units on a scale | Disposable Urethral Support Device | Reusable Underwear | Pelvic Floor Muscle Therapy (PFMT) |
|---|---|---|---|
| Patient Treatment Preference | 23 (19 to 34) | 37 (31 to 38) | 38 (37 to 39) |
The KHQ is a 21-item scale with 9 domains: general health perceptions, incontinence impact, role limitations, physical limitations, social limitations, personal relationships, emotions, Sleep/Energy, and severity measures and an 11-item symptom severity score. (Hebbar et al., 2015) Each question has four options "not at all", "a little", "moderately" and "a lot". (numerically 1-4) The general health perception domain has five choices ("very good", "good", "fair", "bad" and "very bad") (numerically 1-5). The scores are then converted to "out of 100" with accepted formulas. For example for Q1 the overall score = ((actual score-1)/4)\*100 In the KHQ, a minimum possible score of zero is assigned to the best health and a maximum possible score of 100 is assigned to the worst health. The 0-100 scale is used for each item and each subscale separately. You can then report a total average score across all domains which is reported here
| units on a scale | Disposable Urethral Support Device | Reusable Underwear | Pelvic Floor Muscle Therapy (PFMT) |
|---|---|---|---|
| King's Health Questionnaire | 66.7 ± 23.6 | 33.3 ± 23.6 | 25 ± 14.4 |
Subjects will be asked to document their adherence to therapy on a daily basis and outcome will be reported as the percentage of participants with 100% adherence (responded yes to adherence to therapy all 7 days of therapy on their daily log)
| Participants | Disposable Urethral Support Device | Reusable Underwear | Pelvic Floor Muscle Therapy (PFMT) |
|---|---|---|---|
| Adherence Logs | 3 | 3 | 4 |
At the end of the study, all participants will be asked to indicate how easy it would be to continue practicing their assignment intervention (extremely, very, moderately, somewhat, and not at all easy) and complete the Benefit, Satisfaction, and Willingness to Continue (BSW) questionnaire which asks "would you be willing to continue treatment with this product or therapy?" The reported outcome is the number of participants per group that answered "Yes" to this question.
| Participants | Disposable Urethral Support Device | Reusable Underwear | Pelvic Floor Muscle Therapy (PFMT) |
|---|---|---|---|
| Benefits, Satisfaction, and Willingness to Continue | 0 | 4 | 4 |
Collected over 1 week. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Disposable Urethral Support Device | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) |
| Reusable Underwear | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Pelvic Floor Muscle Therapy (PFMT) | 0/5 (0%) | 0/5 (0%) | 0/5 (0%) |
| Age, Categorical(Participants) | Disposable Urethral Support Device | Reusable Underwear | Pelvic Floor Muscle Therapy (PFMT) | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 4 | 6 | 5 | 15 |
| >=65 years | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Disposable Urethral Support Device | Reusable Underwear | Pelvic Floor Muscle Therapy (PFMT) | Total |
|---|---|---|---|---|
| Mean | 35.7 ± 10.7 | 42.6 ± 17.9 | 34.8 ± 16.7 | 37.3 ± 15.9 |
| Sex: Female, Male(Participants) | Disposable Urethral Support Device | Reusable Underwear | Pelvic Floor Muscle Therapy (PFMT) | Total |
|---|---|---|---|---|
| Female | 4 | 6 | 5 | 15 |
| Male | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Disposable Urethral Support Device | Reusable Underwear | Pelvic Floor Muscle Therapy (PFMT) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 1 |
| White | 4 | 6 | 3 | 13 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Disposable Urethral Support Device | Reusable Underwear | Pelvic Floor Muscle Therapy (PFMT) | Total |
|---|---|---|---|---|
| United States | 4 | 6 | 5 | 15 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2021 to primary completion in Oct 2023, 25 months.
Results were first posted in Oct 2024, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.